A new financing tool dedicated to research and development in infectious diseases has been launched by the European Commission and the European Investment Bank. This tool, called InnovFin Infectious Diseases, enables the European Investment Bank to provide between EUR 7.5m and EUR 75m to innovative players active in developing vaccines, drugs, medical and diagnostic devices, and research infrastructures for combating infectious diseases. Financing is aimed at projects that have passed the pre-clinical stage and for which clinical validation is needed for further development....Read more
Australia’s Department of Health and Department of Agriculture have worked together to come up with the country’s first national antimicrobial resistance strategy, "Responding to the threat of antimicrobial resistance", which lays out plans for action from 2015-2019. The strategy has seven main objectives:Read more
- Increase awareness and understanding of antimicrobial resistance, its implications and actions to combat it, through effective communication, education, and training.
- Implement effective antimicrobial stewardship practices against human health and animal care settings to ensure the appropriate and judicious prescribing, dispensing and administering of antimicrobials.
- Develop nationally coordinated One Health surveillance of antimicrobial resistance and antimicrobial usage.
- Improve infection prevention and control...
An Antimicrobial Innovation Alliance meeting on Stimulating the antimicrobial pipeline: A global perspective will be held on 18 June 2015 at the US Capitol Visitor Center on Capitol Hill in Washington DC, USA. The meeting is also supported by the Review on Antimicrobial Resistance and DRIVE-AB. DRIVE-AB participant Christine Årdal gave a presentation at this meeting on "Creating, Testing and Validating New Economic Models for Antibiotic R&D". The slide set, and others from numerous events, can also be found under "Resources: Slide Sets". Please see the event program for...Read more
On 10 June, 2015, the European BEAM Alliance was officially launched. BEAM represents an alliance of European biotechnology companies that are involved in developing innovative products to tackle antimicrobial resistance. They collaborate with the existing community of stakeholders dedicated to implementing tangible strategies, and give its member companies a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. "BEAM recommends supportive incentives that warrant action by policymakers to stimulate much needed innovation by biotechs." - BEAM Alliance press release Please click to view the press release....Read more
On 2-3 June 2015, members of DRIVE-AB helped to deliver an International Health Summit titled 'A World Without Antibiotics' which was held in Uppsala, Sweden, to bring together experts, delegates of civil society, and industry from around the world to discuss possible solutions to the global threat of antibiotic resistance. At the Uppsala Health Summit 2015, the focus of the dialogue was on how our current state of knowledge and research and development capacity can be used and built upon to take steps on global, national and local levels to reduce the threat from antibiotic resistance. Issues discussed in workshops and in the plenary included:Read more